Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4W8RE)

• Drug Name: MELAGATRAN Drug Info
• Synonyms: Melagatran; 159776-70-2; UNII-2A9QP32MD4; Melagatran [INN]; 2A9QP32MD4; CHEBI:43966; MELAGATRAN (ASTRA-ZENECA); C22H31N5O4; Melagatran (INN); N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID; MEL; H-319/68; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine
• Cross-matching ID:
  PubChem CID: 183797
  ChEBI ID: CHEBI:43966
  CAS Number: CAS 159776-70-2
  TTD Drug ID: DM4W8RE
  VARIDT Drug ID: DR00946

Molecule-Related Drug Atlas

Drug(s) Targeting Cationic trypsinogen (PRSS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[4]
Ulinastatin	DMIQCFG	Premature labour	JB00	Phase 3	[5]
Alpha-1 antitrypsin	DM5EFXZ	Coagulation defect	3B10.0	Phase 2	[6]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[7]
RWJ-56423	DM6BIHE	Asthma	CA23	Discontinued in Phase 1	[8]
Patamostat	DM6HBQJ	Hypotension	BA20-BA21	Terminated	[6]
BMY-44621	DM8R3N0	N. A.	N. A.	Terminated	[9]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[10]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[11]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	DME3PUT	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[13]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[14]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[15]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[16]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[17]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[18]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[19]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[20]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[21]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[22]

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[23]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[24]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[25]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[26]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[27]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[27]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[28]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[29]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[30]
Plasminogen	DM0EFQS	Alzheimer disease	8A20	Phase 2/3	[31]

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[32]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[33]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[34]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[35]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[36]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[37]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[38]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[39]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[40]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[41]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[3]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[44]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[43]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[45]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[43]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[46]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[47]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Inhibitor	[1]
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[2]
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[1]
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Inhibitor	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[3]

References

• [1] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [2] Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53.
• [3] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [4] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [5] Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
• [6] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [7] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [8] Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
• [9] Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
• [10] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [11] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [12] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
• [13] Pfizer. Product Development Pipeline. March 31 2009.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [16] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [17] Company report (Portola)
• [18] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [19] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [20] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [21] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [22] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
• [23] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [24] The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
• [25] Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
• [26] Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
• [27] Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
• [28] Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
• [29] Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
• [30] Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
• [31] Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
• [32] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [33] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [34] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [35] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [36] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [37] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [38] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [39] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [40] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [41] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
• [42] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [43] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [44] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [45] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [46] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [47] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.